Presenter: Vamsidhar Velcheti, MD, FACP, Staff Physician, Hematology and Oncology; Associate Director, Center for Immuno-Oncology Research
Taussi Cancer Institute | Cleveland Clinic
Immunotherapies are now standard of care for many tumor types. However, recognizing patients who would benefit the most from these therapies and patients at risk for developing immune-related adverse events (irAEs) remains a challenge. In this lung-cancer-focused webinar, Vamsidhar Velcheti, MD, Professor of Medicine, Cleveland Clinic Lerner College of Medicine, will discuss checkpoint inhibitor biomarkers in use today, as well as biomarkers in development for assessing patient response to their I-O therapy. Learn about cutting-edge research underway on the use of biomarkers to identify patients who could be at high risk for developing irAEs.
View On-Demand Webinar Download Slides